insights_auto
Why is BT3 up 3.19%?
Dive Deeperchevron_right
BT3:FRA
Lineage Cell Therapeutics Inc
€0.84
arrow_upward
+3.19%(+0.026) 1D
Oct 1, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BT3...
Open
€0.84
High
€0.84
Low
€0.84
Mkt. cap
227.65M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.69
52-wk low
€0.81
No. of employees
75
Open
€0.84
High
€0.84
Low
€0.84
Mkt. cap
227.65M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.69
52-wk low
€0.81
No. of employees
75
News stories
From web sources and news partners
BigGo Finance
·
42 minutes ago
Dow Rebounds After 4 Sessions, Up $20 as Rise in Long-Term Yields Pauses
marketscreener.com
·
49 minutes ago
S&P 500 Snaps 3-Day Losing Streak as Yields Fall
24/7 Wall St.
·
2 hours ago
S&P 500 Closes at 7,678 as Growth Leads on Quarter-Open Day
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc